Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 3/20 | 0.51 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.41 |
| ▸ | USP7 | Q93009 | 3/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | TNF | P01375 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29900568 | 1.00 | TACR1 (0.51) | TACR1RORCPDE4BADAM17USP7 | |
| SCHEMBL23923927 | 0.88 | TRPV1 (0.44) | TRPV1 | |
| SCHEMBL23923925 | 0.88 | TRPV1 (0.44) | TRPV1 | |
| SCHEMBL23951728 | 0.87 | TACR1 (0.57) | TACR1RORCPDE4B | |
| SCHEMBL28932943 | 0.87 | TACR1 (0.57) | TACR1RORCPDE4B | |
| SCHEMBL23951650 | 0.87 | TACR1 (0.57) | TACR1RORCPDE4B | |
| SCHEMBL23951496 | 0.87 | TACR1 (0.49) | TACR1RORCPDE4BUSP7TRPV1 | |
| SCHEMBL23951597 | 0.87 | TACR1 (0.49) | TACR1RORCPDE4BUSP7TRPV1 | |
| SCHEMBL23951831 | 0.87 | TACR1 (0.49) | TACR1RORCPDE4BUSP7TRPV1 | |
| SCHEMBL28932940 | 0.87 | TACR1 (0.49) | TACR1RORCPDE4BUSP7TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S.R.L. (IT) | 2022-07-07 | — | — | US | disclosed |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S R L (IT) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | TACR1 3676/4885RORC 46/4885PDE4B 2677/4885 |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | TACR1 3676/4885RORC 46/4885PDE4B 2677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.